Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial).

JNCI Cancer Spectr · 2026 · PMC13242927 · PMID 42093085

Europe PMC DOI

hedged sentence

0.0880

closest p · 1.8× alpha

0.0880

boldest claim

The sentences

borderline non-significantP = .088so close (0.05 < p ≤ 0.1)

Statistically significant changes were observed during the study treatment only for improved emotional functioning ( P = .014), a borderline non-significant worsening of appetite loss ( P = .088), as assessed by the EORTC QLQ C30, and an increase in alopecia ( P = .012), as evaluated by the LC13.

also in 434 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.